Time Course of In Vivo 5-HTT Transporter Occupancy by Fluvoxamine

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Psychopharmacology

• Publication date

  2006-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1097/01.jcp.0000203201.34323.d3PMID 16633150
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The necessary parameters for estimating the time-course of receptor occupancy.

  2005cited by this paper
• Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

  2004influential reference
• Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain

  2003cited by this paper
• [11C]‐DASB, a tool for in vivo measurement of SSRI‐induced occupancy of the serotonin transporter: PET characterization and evaluation in cats

  2003cited by this paper
• High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.

  2003cited by this paper
• Template-Based Method for Multiple Volumes of Interest of Human Brain PET Images

  2002cited by this paper
• Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines.

  2000cited by this paper
• Effects of SSRIs on sexual function: a critical review.

  1999cited by this paper
• Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy.

  1998cited by this paper
• Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

  1998cited by this paper
• Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.

  1997cited by this paper
• Serotonin reuptake inhibitor withdrawal.

  1996cited by this paper

• Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants

  2024influential citation
• Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

  2021cites this paper
• The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review

  2021cites this paper
• Molecular Imaging of Depressive Disorders

  2020cites this paper
• PET technology for drug development in psychiatry

  2020cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2018cites this paper
• Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO

  2018cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2017cites this paper
• Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs

  2016influential citation
• Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [(11)C]DASB.

  2016influential citation
• Early Development of Dietary Supplements for Preventing Postpartum Depression

  2015cites this paper
• AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.

  2014cites this paper
• Occupancy of serotonin transporter by tramadol: a positron emission tomography study with [11C]DASB.

  2014influential citation
• PET studies of the serotonin system in major depression and its treatment

  2014influential citation
• The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy

  2013cites this paper
• IMAGING DRUG DELIVERY TO THE CNS USING TRANSLATIONAL POSITRON EMISSION TOMOGRAPHY STUDIES

  2013cites this paper
• Modeling of PET data in CNS drug discovery and development

  2013cites this paper
• Neuroimaging High Risk States for Suicide

  2012cites this paper
• Imaging treatment effects in depression

  2012cites this paper
• Central Nervous System Drug Evaluation Using Positron Emission Tomography

  2011cites this paper
• Decrease in brain distribution of fluvoxamine in experimental hyperlipidemic rats.

  2011cites this paper
• AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011

  2011cites this paper
• Imaging serotonergic transmission with [11C]DASB-PET in depressed and non-depressed patients infected with HIV

  2010cites this paper
• Utility of small-animal positron emission tomographic imaging of rats for preclinical development of drugs acting on the serotonin transporter.

  2009cites this paper
• Management of obsessive-compulsive disorder with fluvoxamine extended release

  2009cites this paper
• Research on Molecular Imaging of Cancer

  2008cites this paper
• Pharmacokinetic–pharmacodynamic modelling of fluvoxamine 5‐HT transporter occupancy in rat frontal cortex

  2008influential citation
• Dose-escalation in the picture : pharmacological and imaging studies in depression

  2008cites this paper
• Imaging the serotonin transporter during major depressive disorder and antidepressant treatment.

  2007cites this paper
• Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study

  2007cites this paper